High doses of botulinum toxin effectively treat disabling up-going toe

J Neurol Sci. 2008 Jan 15;264(1-2):118-20. doi: 10.1016/j.jns.2007.08.013. Epub 2007 Sep 19.

Abstract

Involuntary up-going toe can be a disabling consequence of dystonia or spasticity. In this study, we treated eight patients with botulinum toxin (BTx) in the extensor hallucis longus (EHL) and applied objective and subjective outcome measures to determine treatment efficacy. Using 100% higher doses than generally reported, patients noted 62+/-20% mean benefit and scores on a modified Fahn-Marsden Dystonia Scale decreased significantly by 1.8+/-0.6 (p=0.010). High doses (up to 160 BTx A units) into the EHL were safe and dosage correlated highly and significantly with treatment efficacy (rho=0.859, p=0.006).

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Dyskinesia Agents / administration & dosage
  • Botulinum Toxins / administration & dosage*
  • Child
  • Dose-Response Relationship, Drug
  • Dystonic Disorders / drug therapy*
  • Dystonic Disorders / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / physiopathology
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / physiopathology
  • Toes / innervation
  • Toes / physiopathology*
  • Treatment Outcome

Substances

  • Anti-Dyskinesia Agents
  • Botulinum Toxins